+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Bacterial Meningitis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 180 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294576
The bacterial meningitis market size was valued at USD 148.99 million in 2026 and is estimated to grow from USD 154.19 million in 2027 to reach USD 189.61 million by 2032, at a CAGR of 4.22% during the forecast period (2027-2032). This report is Segmented by Modality (Treatment, Diagnostic Modality), Age Group (Children and Adolescents, Adults, Older Adults), End-User (Hospitals, Specialty Clinics, Diagnostic Laboratories, Other End-Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Bacterial Meningitis Market Trends and Insights

Expansion of Conjugate and Combination Vaccination Programs

The bacterial meningitis market is gaining support from vaccines that combine coverage for several meningococcal serogroups in one product. The U.S. Food and Drug Administration approved GSK’s Penmenvy in February 2025 for people aged 10 to 25 years. The Advisory Committee on Immunization Practices recommended its use in April 2025 when MenACWY and MenB vaccination are both indicated.In August 2026, the European Commission approved MenQuadfi for infants from 6 weeks of age, extending Sanofi’s pediatric vaccine offering in Europe. Nigeria introduced Serum Institute of India’s heat-stable MenFive vaccine in March 2024, and Niger followed with a national preventive campaign in 2025.These programs reduce cold-chain dependence and create ongoing needs for serogroup surveillance after rollout.

Rapid Syndromic Diagnostics Supporting Empiric-Therapy De-Escalation

Rapid syndromic testing is increasing the clinical value of the bacterial meningitis market by reducing the time required to identify likely pathogens. QIAGEN received U.S. clearance for the QIAstat-Dx Meningitis and Encephalitis Panel in November 2024. The panel introduced another multiplex testing option alongside bioMérieux’s FilmArray platform. A 2025 study found that the BIOFIRE FILMARRAY Meningitis and Encephalitis Panel reduced per-episode costs by 8.4% in adults and 15.7% in children compared with real-time PCR.Earlier identification can help clinicians narrow antibiotic treatment and reduce unnecessary corticosteroid exposure. The bacterial meningitis market, therefore, benefits from testing coverage that addresses emerging pathogens as well as faster turnaround times.

High Cost of Molecular Instruments, Reagents, and Vaccine Procurement

High instrument, reagent, and vaccine costs restrict access across the bacterial meningitis market, especially where the disease burden is greatest. Multiplex PCR testing can cost USD 94 per run, while analyzer purchases require substantial upfront spending. These costs can prevent public hospitals from adopting molecular platforms when testing volumes are uncertain. Pentavalent meningococcal vaccines also cost more than older quadrivalent products, which places pressure on public procurement budgets. Limited cerebrospinal fluid sampling capacity in neonates and lower-resource facilities further reduces the number of patients who can benefit from laboratory confirmation. Heat-stable, low-volume assays could reduce this limitation over time, but these tools remain under development. Cold-chain fragility and a concentrated supply base can further disrupt access during outbreak periods.

Other drivers and restraints analyzed in the detailed report include:

  1. High Mortality and Long-Term Disability Burden
  2. Recurrent Meningococcal Epidemics and Outbreak Preparedness
  3. Reimbursement and Procurement Gaps for Rapid Point-of-Care Testing

Segment Analysis

Treatment held 54.25% of the bacterial meningitis market share in 2026, reflecting the central role of antibiotics and corticosteroids in acute care. Intravenous broad-spectrum cephalosporins, including ceftriaxone, remain the empiric treatment base across care settings. Dexamethasone is used to reduce neuroinflammation and the risk of sequelae in many developed-market protocols. Vaccine procurement is expanding within treatment following recent product approvals and pediatric indication extensions.

Diagnostic modality is projected to grow at a 5.16% CAGR from 2027 to 2032, the fastest rate among type categories. Lumbar puncture and blood culture remain core diagnostic approaches, but PCR has become a significant complementary method. This is particularly relevant after antibiotics have reduced culture sensitivity. A 2025 study at a North Indian tertiary center detected pathogens in 9.3% of cerebrospinal fluid samples using multiplex PCR, compared with 2.3% using culture. Serology and imaging remain useful in atypical cases, particularly for older adults and immunocompromised patients.

Complete Report Scope:

  • By Modality
    • Treatment
      • Antibiotics
      • Corticosteroids
      • Vaccines
      • Supportive Care
      • Antiviral Medication
    • Diagnostic Modality
      • Lumbar Puncture
      • Blood Cultures
      • Polymerase Chain Reaction
      • Serological Tests
      • Imaging Techniques
  • By Age Group
    • Children and Adolescents
    • Adults
    • Older Adults
  • By End-User
    • Hospitals
    • Specialty Clinics
    • Diagnostic Laboratories
    • Other End-Users
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 46.22% of the bacterial meningitis market share in 2026, supported by hospital molecular infrastructure, established vaccination schedules, and reimbursement for culture and PCR testing. The United States reported 463 confirmed or probable meningococcal cases in 2025, its second-highest count. Canada updated its guidance on quadrivalent conjugate meningococcal vaccines in March 2025. The U.S. recommendation for Penmenvy and FDA clearance for QIAstat-Dx created overlapping vaccine and diagnostic procurement activity. Mexico offers additional opportunities as public health investment expands diagnostic laboratory infrastructure.

Europe has significant revenue from Germany, the United Kingdom, France, Italy, and Spain. Regulation under IVDR and rigorous vaccine assessment support premium product requirements despite lower incidence levels. Whole-genome sequencing of Neisseria meningitidis is routinely used by major European health systems. An observational study in Lombardy found rising Streptococcus pneumoniae meningitis incidence among adults older than 65 years from 2014 to 2024. Eastern European markets remain less penetrated for advanced diagnostics, which leaves room for future panel adoption.

Asia-Pacific is projected to grow at a 6.13% CAGR through 2032, making it the fastest-growing regional bacterial meningitis market. The World Health Organization South-East Asia Region recorded 438,000 meningitis cases and 22,689 deaths in 2023. Growth reflects a shift from underdiagnosis to more complete diagnosis, particularly in reference laboratories. India’s multiplex PCR evidence supports this change in clinical practice. In the Middle East and Africa, Gavi and the International Coordinating Group stockpile remain central procurement channels. South America’s post-pandemic rise in serogroup B disease is also strengthening the case for vaccine and diagnostic investment.



List of Companies Covered in this Report:

  1. Abbott Laboratories
  2. Beckton Dickinson
  3. Bharat Biotech International Limited
  4. bioMerieux S.A.
  5. Bio-Rad Laboratories
  6. CSL Behring
  7. DiaSorin
  8. Roche
  9. GlaxoSmithKline
  10. Hualan Biological
  11. Incepta Pharmaceuticals Limited
  12. Merck
  13. Pfizer
  14. QIAGEN
  15. Sanofi
  16. Seegene
  17. Serum Institute of India
  18. Siemens Healthineers
  19. Thermo Fisher Scientific
  20. Walvax Biotechnology Co., Ltd.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Mortality and Long-Term Disability Burden
4.2.2 Recurrent Meningococcal Epidemics and Outbreak Preparedness
4.2.3 Expansion of Conjugate and Combination Vaccination Programs
4.2.4 Rapid Syndromic Diagnostics Supporting Empiric-Therapy De-Escalation
4.2.5 Ultra-Low-Volume and Heat-Stable Testing for Meningitis Belt Access
4.2.6 Post-Vaccination Serogroup Surveillance and Pathogen Genomic Monitoring
4.3 Market Restraints
4.3.1 High Cost of Molecular Instruments, Reagents, and Vaccine Procurement
4.3.2 Limited Cerebrospinal-Fluid Sampling Capacity in Neonates and Low-Resource Settings
4.3.3 Reimbursement and Procurement Gaps for Rapid Point-of-Care Testing
4.3.4 Critical-Input Concentration and Cold-Chain Fragility
4.4 Supply/Value Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Modality
5.1.1 Treatment
5.1.1.1 Antibiotics
5.1.1.2 Corticosteroids
5.1.1.3 Vaccines
5.1.1.4 Supportive Care
5.1.1.5 Antiviral Medication
5.1.2 Diagnostic Modality
5.1.2.1 Lumbar Puncture
5.1.2.2 Blood Cultures
5.1.2.3 Polymerase Chain Reaction
5.1.2.4 Serological Tests
5.1.2.5 Imaging Techniques
5.2 By Age Group
5.2.1 Children and Adolescents
5.2.2 Adults
5.2.3 Older Adults
5.3 By End-User
5.3.1 Hospitals
5.3.2 Specialty Clinics
5.3.3 Diagnostic Laboratories
5.3.4 Other End-Users
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
6.3.1 Abbott Laboratories
6.3.2 Becton, Dickinson and Company
6.3.3 Bharat Biotech International Limited
6.3.4 bioMerieux S.A.
6.3.5 Bio-Rad Laboratories, Inc.
6.3.6 CSL Limited
6.3.7 DiaSorin S.p.A.
6.3.8 F. Hoffmann-La Roche Ltd.
6.3.9 GSK plc
6.3.10 Hualan Biological Engineering Inc.
6.3.11 Incepta Pharmaceuticals Limited
6.3.12 Merck & Co., Inc.
6.3.13 Pfizer Inc.
6.3.14 QIAGEN N.V.
6.3.15 Sanofi S.A.
6.3.16 Seegene Inc.
6.3.17 Serum Institute of India Pvt. Ltd.
6.3.18 Siemens Healthineers AG
6.3.19 Thermo Fisher Scientific Inc.
6.3.20 Walvax Biotechnology Co., Ltd.
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bharat Biotech International Limited
  • bioMerieux S.A.
  • Bio-Rad Laboratories, Inc.
  • CSL Limited
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Hualan Biological Engineering Inc.
  • Incepta Pharmaceuticals Limited
  • Merck & Co., Inc.
  • Pfizer Inc.
  • QIAGEN N.V.
  • Sanofi S.A.
  • Seegene Inc.
  • Serum Institute of India Pvt. Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Walvax Biotechnology Co., Ltd.